Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 77Recruiting 29Terminated 26Active not recruiting 13Unknown 12Withdrawn 10Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Neoplasms 8Pancreatic Neoplasms 4Myelodysplastic Syndromes 3Melanoma 3Leukemia, Myeloid, Acute 3Leukemia 3Glioblastoma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Stomach Neoplasms 2Sarcoma 2Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Lung Neoplasms 2Colorectal Neoplasms 2Vulvar Neoplasms 1Vaginitis 1Uterine Cervical Neoplasms 1Tongue Neoplasms 1Solid Tumors 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rectal Neoplasms 1Primary Myelofibrosis 1

Interventions

pembrolizumab 1CA-4948 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Suspended × Brain Neoplasms × Clear all
NCT05669352 2025-04-04

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

University of Florida

Phase 1/2 Suspended
29 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡